Bicara Therapeutics’ (BCAX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report released on Wednesday,Benzinga reports. Wedbush currently has a $31.00 target price on the stock.

Several other research analysts have also commented on the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. HC Wainwright lifted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Up 2.7 %

Shares of NASDAQ BCAX opened at $13.48 on Wednesday. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The company’s 50 day simple moving average is $14.98.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently made changes to their positions in the stock. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $31,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics during the 4th quarter valued at $33,000. Ameritas Investment Partners Inc. bought a new stake in Bicara Therapeutics during the 4th quarter valued at $35,000. Virtus ETF Advisers LLC bought a new stake in Bicara Therapeutics during the 4th quarter valued at $69,000. Finally, SG Americas Securities LLC bought a new stake in Bicara Therapeutics during the 4th quarter valued at $147,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.